|
[1]
|
Immunomodulation in age‐related disorders and nanotechnology interventions
WIREs Nanomedicine and Nanobiotechnology,
2023
DOI:10.1002/wnan.1840
|
|
|
|
|
[2]
|
Nanotechnology‐empowered therapeutics targeting neurodegenerative diseases
WIREs Nanomedicine and Nanobiotechnology,
2023
DOI:10.1002/wnan.1907
|
|
|
|
|
[3]
|
The Role of Biomaterials in Treating Lou Gehrig’s Disease
Archives of Neuroscience,
2022
DOI:10.5812/ans-131625
|
|
|
|
|
[4]
|
Multifunctional Nanocarriers
2022
DOI:10.1016/B978-0-323-85041-4.00012-3
|
|
|
|
|
[5]
|
Formulation, Characterization, and Cytotoxicity Evaluation of Lactoferrin Functionalized Lipid Nanoparticles for Riluzole Delivery to the Brain
Pharmaceutics,
2022
DOI:10.3390/pharmaceutics14010185
|
|
|
|
|
[6]
|
Liposome delivery to the brain with rapid short-pulses of focused ultrasound and microbubbles
Journal of Controlled Release,
2022
DOI:10.1016/j.jconrel.2021.12.005
|
|
|
|
|
[7]
|
Applications of Various Types of Nanomaterials for the Treatment of Neurological Disorders
Nanomaterials,
2022
DOI:10.3390/nano12132140
|
|
|
|
|
[8]
|
Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?
Journal of Personalized Medicine,
2022
DOI:10.3390/jpm12071071
|
|
|
|
|
[9]
|
Immunomodulation in age‐related disorders and nanotechnology interventions
WIREs Nanomedicine and Nanobiotechnology,
2022
DOI:10.1002/wnan.1840
|
|
|
|
|
[10]
|
Multifunctional Nanocarriers
2022
DOI:10.1016/B978-0-323-85041-4.00012-3
|
|
|
|
|
[11]
|
Phytoantioxidants and Nanotherapeutics
2022
DOI:10.1002/9781119811794.ch20
|
|
|
|
|
[12]
|
The Role of Biomaterials in Treating Lou Gehrig’s Disease
Archives of Neuroscience,
2022
DOI:10.5812/ans-131625
|
|
|
|
|
[13]
|
Theory and Applications of Nonparenteral Nanomedicines
2021
DOI:10.1016/B978-0-12-820466-5.00012-0
|
|
|
|
|
[14]
|
Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives
Molecular Pharmaceutics,
2021
DOI:10.1021/acs.molpharmaceut.1c00297
|
|
|
|
|
[15]
|
The Prospect of Nanoparticle Systems for Modulating Immune Cell Polarization During Central Nervous System Infection
Frontiers in Immunology,
2021
DOI:10.3389/fimmu.2021.670931
|
|
|
|
|
[16]
|
Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives
Molecular Pharmaceutics,
2021
DOI:10.1021/acs.molpharmaceut.1c00297
|
|
|
|
|
[17]
|
Microglia-targeting nanotherapeutics for neurodegenerative diseases
APL Bioengineering,
2020
DOI:10.1063/5.0013178
|
|
|
|
|
[18]
|
Antioxidants and Nanotechnology: Promises and Limits of Potentially Disruptive Approaches in the Treatment of Central Nervous System Diseases
Advanced Healthcare Materials,
2020
DOI:10.1002/adhm.201901589
|
|
|
|
|
[19]
|
Microglia-targeting nanotherapeutics for neurodegenerative diseases
APL Bioengineering,
2020
DOI:10.1063/5.0013178
|
|
|
|
|
[20]
|
Antioxidants and Nanotechnology: Promises and Limits of Potentially Disruptive Approaches in the Treatment of Central Nervous System Diseases
Advanced Healthcare Materials,
2020
DOI:10.1002/adhm.201901589
|
|
|
|
|
[21]
|
Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases
European Journal of Pharmaceutics and Biopharmaceutics,
2020
DOI:10.1016/j.ejpb.2020.01.005
|
|
|
|
|
[22]
|
Nanobiotechnology in Neurodegenerative Diseases
2019
DOI:10.1007/978-3-030-30930-5_4
|
|
|
|
|
[23]
|
Advances in Personalized Nanotherapeutics
2017
DOI:10.1007/978-3-319-63633-7_6
|
|
|
|
|
[24]
|
A Review of the Potential Role of Nano-Enabled Drug Delivery Technologies in Amyotrophic Lateral Sclerosis: Lessons Learned from Other Neurodegenerative Disorders
Journal of Pharmaceutical Sciences,
2015
DOI:10.1002/jps.24322
|
|
|
|
|
[25]
|
Current nano/biotechnological approaches in amyotrophic lateral sclerosis
Biomedical Engineering Letters,
2013
DOI:10.1007/s13534-013-0114-y
|
|
|
|